Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

News|Articles|October 28, 2025

Psychosocial Burden of HS and the Importance of Early Treatment

Author(s)Sponsored by Novartis Pharmaceuticals Corporation

In this Dermatology Times Partner Perspectives video, Dr. Martina Porter examines the profound psychosocial burden of hidradenitis suppurativa and underscores the importance of early diagnosis and treatment to improve patients’ quality of life.

Episodes in this series

EP. 1 Overview of HS and Moderate Disease

EP. 1 Overview of HS and Moderate Disease

EP. 2 Psychosocial Burden of HS and the Importance of Early Treatment

EP. 2 Psychosocial Burden of HS and the Importance of Early Treatment

EP. 3 Diagnosis and Treatment of Moderate HS

EP. 3 Diagnosis and Treatment of Moderate HS

EP. 4 Understanding Moderate Hidradenitis Suppurativa: Diagnosis, Impact, and Treatment

EP. 4 Understanding Moderate Hidradenitis Suppurativa: Diagnosis, Impact, and Treatment

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

ANZUPGO (delgocitinib): A New Era in Moderate-to-Severe Chronic Hand Eczema Treatment (Article)

November 3rd 2025

Sponsored Content

Understanding Moderate Hidradenitis Suppurativa: Diagnosis, Impact, and Treatment

BySponsored by Novartis Pharmaceuticals Corporation

October 28th 2025

Diagnosis and Treatment of Moderate HS

BySponsored by Novartis Pharmaceuticals Corporation

October 28th 2025

Overview of HS and Moderate Disease

BySponsored by Novartis Pharmaceuticals Corporation

October 28th 2025

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

New Frontiers in CSCC: Experts Weigh Immunotherapy Options and Collaborative Referral Pathways